Showing results (401-410 of 433) with videos related to
Sort By:
Pageof 44
Cancer Research|November 11, 1998
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic miceM Liu, M S Bryant, J Chen, et al.Journal of Medicinal Chemistry|April 4, 1998
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazineA K Mallams, R R Rossman, R J Doll, et al.The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.American Journal of Hematology|October 10, 2012
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemiaSonia Fabris, Laura Mosca, Giovanna Cutrona, et al.Journal of the American Academy of Dermatology|July 16, 2011
Total body skin examination for skin cancer screening in patients with focused symptomsGiuseppe Argenziano, Iris Zalaudek, Rainer Hofmann-Wellenhof, et al.Frontiers in Immunology|February 2, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern ItalyVito Longo, Carminia Maria Della Corte, Alessandro Russo, et al.Science Translational Medicine|January 10, 2024
mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduriaSonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, et al.Physical Review Letters|February 16, 2024
Evidence of a Hardening in the Cosmic Ray Proton Spectrum at around 166 TeV Observed by the GRAPES-3 ExperimentF Varsi, S Ahmad, M Chakraborty, et al.Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.Clinical Genitourinary Cancer|November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 StudyBrigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.Pageof 44